Canaccord Genuity Reiterates Buy Rating on Regulus Therapeutics (RGLS)
Tweet Send to a Friend
Canaccord Genuity analyst Whitney Ijem reiterated a Buy rating and $28.00 price target on Regulus Therapeutics (NASDAQ: RGLS).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
